celecoxib has been researched along with Recrudescence in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 9.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer." | 9.16 | Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 9.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure." | 7.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "Epileptic seizures constitute an important problem in pediatric neurology during the developmental period." | 5.48 | Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats. ( Caballero-Chacón, S; Feria-Romero, IA; Morales-Sosa, M; Orozco-Suárez, S; Vega-García, A, 2018) |
| "Nephrotic syndrome, with or without concomitant tubulointerstitial nephritis, is a rare renal adverse effect of NSAIDs." | 5.37 | Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. ( Knotek, M; Ljubanovic, D; Mihovilovic, K, 2011) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 5.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer." | 5.16 | Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012) |
| " The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events." | 5.15 | C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011) |
| "We performed a placebo-controlled pilot trial to evaluate the safety of celecoxib in patients with ulcerative colitis in remission who had a present or past history of nonspecific arthritis, arthralgia, or other condition amenable to nonsteroidal anti-inflammatory drug therapy." | 5.12 | Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. ( Bloom, BJ; Brynskov, J; Kent, JD; Lorenz, RG; Robbins, JL; Sandborn, WJ; Steidle, GM; Stenson, WF, 2006) |
| " Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)." | 5.11 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| "Although only rofecoxib use was associated with an increased risk of myocardial infarction in those without a previous event, both rofecoxib and celecoxib were associated with an excess risk of acute myocardial infarction for current users with a history of myocardial infarction." | 3.74 | The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. ( Brophy, JM; Lévesque, LE; Zhang, B, 2007) |
| "Celecoxib seems safer than rofecoxib and NSAIDs in elderly patients with congestive heart failure." | 3.73 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. ( Hudson, M; Pilote, L; Richard, H, 2005) |
| "Celecoxib is a cyclooxygenase-2-specific inhibitor indicated to treat acute pain and pain secondary to osteoarthritis and rheumatoid arthritis." | 2.82 | Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial. ( Bodeker, KL; Trask, DK; Van Daele, DJ, 2016) |
| "Treatment of celecoxib with a proton pump inhibitor is safer than treatment with nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and cardiovascular patients who mostly also take acetylsalicylic acid." | 2.52 | [Gastrointestinal bleeding]. ( Lanas, Á, 2015) |
| "Surveillance bronchoscopy identified a recurrence." | 1.56 | Recurrent endobronchial inflammatory myofibroblastic tumors: Novel treatment options. ( Arteta, M; Mychaliska, GB; Rabah, R; Ramirez, IA; Rubalcava, NS, 2020) |
| "Celecoxib treatment (100 mg/day) was initiated for local pain management." | 1.51 | Celecoxib as a Potential Treatment for Intractable Lymphatic Malformation. ( Imamura, M; Kawamura, J; Kawano, Y; Nishikawa, T; Okamoto, Y; Yamasaki, Y; Yoneyama, T, 2019) |
| "Advanced epithelial ovarian cancer (EOC) is associated with dismal outcome and progression-free survival (PFS) shortens with each subsequent relapse." | 1.51 | Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis. ( Bhatla, N; Khurana, S; Kumar, L; Kumar, S; Malik, PS; Ray, MD; Sharma, A, 2019) |
| "Epileptic seizures constitute an important problem in pediatric neurology during the developmental period." | 1.48 | Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats. ( Caballero-Chacón, S; Feria-Romero, IA; Morales-Sosa, M; Orozco-Suárez, S; Vega-García, A, 2018) |
| "Heterotopic ossification (HO) recurrence after joint surgery is always a disturbing problem for patients and surgeons." | 1.42 | The efficacy of celecoxib in preventing heterotopic ossification recurrence after open arthrolysis for post-traumatic elbow stiffness in adults. ( Cai, J; Fan, C; Li, F; Liu, S; Ruan, H; Sun, Y, 2015) |
| "Nephrotic syndrome, with or without concomitant tubulointerstitial nephritis, is a rare renal adverse effect of NSAIDs." | 1.37 | Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs. ( Knotek, M; Ljubanovic, D; Mihovilovic, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (52.94) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Haney, M | 1 |
| Bedi, G | 1 |
| Cooper, ZD | 1 |
| Herrmann, ES | 1 |
| Reed, SC | 1 |
| Foltin, RW | 1 |
| Kingsley, PJ | 1 |
| Marnett, LJ | 1 |
| Patel, S | 1 |
| Imamura, M | 1 |
| Okamoto, Y | 1 |
| Nishikawa, T | 1 |
| Yoneyama, T | 1 |
| Yamasaki, Y | 1 |
| Kawamura, J | 1 |
| Kawano, Y | 1 |
| Ramirez, IA | 1 |
| Rubalcava, NS | 1 |
| Mychaliska, GB | 1 |
| Rabah, R | 1 |
| Arteta, M | 1 |
| Sharma, A | 1 |
| Malik, PS | 1 |
| Khurana, S | 1 |
| Kumar, S | 1 |
| Bhatla, N | 1 |
| Ray, MD | 1 |
| Kumar, L | 1 |
| Chan, FKL | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Lam, K | 1 |
| Wong, GLH | 1 |
| Ng, SC | 1 |
| Lee, V | 1 |
| Au, KWL | 1 |
| Cheong, PK | 1 |
| Suen, BY | 2 |
| Chan, H | 1 |
| Kee, KM | 1 |
| Lo, A | 1 |
| Wong, VWS | 1 |
| Wu, JCY | 1 |
| Kyaw, MH | 1 |
| Steurer, J | 1 |
| Morales-Sosa, M | 1 |
| Orozco-Suárez, S | 1 |
| Vega-García, A | 1 |
| Caballero-Chacón, S | 1 |
| Feria-Romero, IA | 1 |
| Kvasnovsky, CL | 1 |
| Aujla, U | 1 |
| Bjarnason, I | 1 |
| Sun, Y | 1 |
| Cai, J | 1 |
| Li, F | 1 |
| Liu, S | 1 |
| Ruan, H | 1 |
| Fan, C | 1 |
| Lanas, Á | 1 |
| Van Daele, DJ | 1 |
| Bodeker, KL | 1 |
| Trask, DK | 1 |
| Glück, S | 1 |
| Mihovilovic, K | 1 |
| Ljubanovic, D | 1 |
| Knotek, M | 1 |
| Legge, F | 1 |
| Paglia, A | 1 |
| D'Asta, M | 1 |
| Fuoco, G | 1 |
| Scambia, G | 1 |
| Ferrandina, G | 1 |
| Chan, AT | 1 |
| Sima, CS | 1 |
| Zauber, AG | 1 |
| Ridker, PM | 1 |
| Hawk, ET | 1 |
| Bertagnolli, MM | 1 |
| Thompson, P | 1 |
| Roe, DJ | 1 |
| Fales, L | 1 |
| Buckmeier, J | 1 |
| Wang, F | 1 |
| Hamilton, SR | 1 |
| Bhattacharyya, A | 1 |
| Green, S | 1 |
| Hsu, CH | 1 |
| Chow, HH | 1 |
| Ahnen, DJ | 1 |
| Boland, CR | 1 |
| Heigh, RI | 1 |
| Fay, DE | 1 |
| Martinez, ME | 1 |
| Jacobs, E | 1 |
| Ashbeck, EL | 1 |
| Alberts, DS | 1 |
| Lance, P | 1 |
| Peres, MF | 1 |
| Silberstein, SD | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Senna, G | 1 |
| Bilò, MB | 1 |
| Antonicelli, L | 1 |
| Schiappoli, M | 1 |
| Crivellaro, MA | 1 |
| Bonadonna, P | 1 |
| Dama, AR | 1 |
| Chan, FK | 1 |
| Hung, LC | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 1 |
| Leung, WK | 1 |
| Lee, YT | 1 |
| To, KF | 1 |
| Chung, SC | 1 |
| Sung, JJ | 1 |
| Hudson, M | 1 |
| Richard, H | 1 |
| Pilote, L | 1 |
| Prince, HM | 1 |
| Mileshkin, L | 1 |
| Roberts, A | 1 |
| Ganju, V | 1 |
| Underhill, C | 1 |
| Catalano, J | 1 |
| Bell, R | 1 |
| Seymour, JF | 1 |
| Westerman, D | 1 |
| Simmons, PJ | 1 |
| Lillie, K | 1 |
| Milner, AD | 1 |
| Iulio, JD | 1 |
| Zeldis, JB | 1 |
| Ramsay, R | 1 |
| Lai, KC | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Wong, BC | 1 |
| Hu, WH | 1 |
| Wong, WM | 1 |
| Chan, AO | 1 |
| Wong, J | 1 |
| Lam, SK | 1 |
| Sandborn, WJ | 1 |
| Stenson, WF | 1 |
| Brynskov, J | 1 |
| Lorenz, RG | 1 |
| Steidle, GM | 1 |
| Robbins, JL | 1 |
| Kent, JD | 1 |
| Bloom, BJ | 1 |
| Pruthi, RS | 1 |
| Derksen, JE | 1 |
| Moore, D | 1 |
| Carson, CC | 1 |
| Grigson, G | 1 |
| Watkins, C | 1 |
| Wallen, E | 1 |
| Gislason, GH | 1 |
| Jacobsen, S | 1 |
| Rasmussen, JN | 1 |
| Rasmussen, S | 1 |
| Buch, P | 1 |
| Friberg, J | 1 |
| Schramm, TK | 1 |
| Abildstrom, SZ | 1 |
| Køber, L | 1 |
| Madsen, M | 1 |
| Torp-Pedersen, C | 1 |
| Brophy, JM | 1 |
| Lévesque, LE | 1 |
| Zhang, B | 1 |
| Buckstein, R | 1 |
| Kerbel, RS | 1 |
| Shaked, Y | 1 |
| Nayar, R | 1 |
| Foden, C | 1 |
| Turner, R | 1 |
| Lee, CR | 1 |
| Taylor, D | 1 |
| Zhang, L | 1 |
| Man, S | 1 |
| Baruchel, S | 1 |
| Stempak, D | 1 |
| Bertolini, F | 1 |
| Crump, M | 1 |
| Ackerman, WE | 1 |
| Ahmad, M | 1 |
| McGettigan, P | 1 |
| Han, P | 1 |
| Jones, L | 1 |
| Whitaker, D | 1 |
| Henry, D | 1 |
| Lantz, MS | 1 |
| Giambanco, V | 1 |
| Mathew, NT | 1 |
| Kailasam, J | 1 |
| Fischer, A | 1 |
| Pfister, AK | 1 |
| Crisalli, RJ | 1 |
| Carter, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660] | Phase 3 | 514 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial[NCT00583453] | Phase 2 | 18 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients[NCT01124435] | Phase 2 | 45 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence[NCT00078897] | Phase 3 | 1,621 participants (Actual) | Interventional | 2005-01-20 | Terminated (stopped due to Concluded - Terminated by PI) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The incidence of post-operative hemorrhage, defined as post-operative bleeding requiring medical intervention or hospitalization during the 10 day post-operative follow-up period. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib 200 mg Tablets | 0 |
| Placebo With Same Dosing Schedule as the Active Comparator Arm | 0 |
Participant reported acetaminophen use and its equivalent. Medication use was collected from reported participant journals. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | mg (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 2074 | 2245 | 2028 | 1418 |
| Placebo Control, Active Comparator | 3006 | 2934 | 3610 | 2483 |
Activity level, reported by participant utilizing a 10-point ordinal scale (0 = no activity, 10 = return to normal activities). Activity level was measured was collected once daily. (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | Activity score (units on a scale) (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 2.8 | 3.1 | 5.4 | 7.4 |
| Placebo Control, Active Comparator | 4.5 | 4.1 | 3.7 | 5.7 |
Pain score as reported by participant, measured on a 10 point scale, where 0 = none and 10 = unbearable, collected once daily. (NCT00583453)
Timeframe: day of procedure through post-operative day 10
| Intervention | pain score (units on a scale) (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum pain, day 1 | maximum pain, averaged across days 2 to 4 | maximum pain, averaged across days 5 to 7 | maximum pain, averaged across days 8 to 10 | Average pain, day 1 | Average pain, averaged across days 2 to 4 | Average pain, averaged across days 5 to 7 | Average pain, averaged across days 8 to 10 | Pain with drinking, day 1 | Pain with drinking, averaged across days 2 to 4 | Pain with drinking, averaged across days 5 to 7 | Pain with drinking, averaged across days 8 to 10 | Activity, day 1 | |
| Celecoxib 200 mg Tablets | 5.0 | 5.1 | 4.4 | 3.6 | 6.1 | 6.2 | 6.1 | 4.9 | 5.7 | 5.4 | 4.9 | 3.9 | 2.8 |
| Placebo With Same Dosing Schedule as the Active Comparator Arm | 6.0 | 6.0 | 5.9 | 4.0 | 7.3 | 7.6 | 7.4 | 5.7 | 6.7 | 6.6 | 5.9 | 4.1 | 4.5 |
Participant reported mophine equivalent use (NCT00583453)
Timeframe: From operative day through 10 days post-operative
| Intervention | mg (Mean) | |||
|---|---|---|---|---|
| Day 1 | Average, days 2 to 4 | Average, days 5 to 7 | Average, days 8 to 10 | |
| Celecoxib as Experimerimental Intervention | 28.9 | 30.4 | 27.8 | 13.2 |
| Placebo Control, Active Comparator | 55.0 | 72.4 | 69.7 | 38.3 |
Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year. (NCT00078897)
Timeframe: One year
| Intervention | ng/mL (Median) |
|---|---|
| Selenium | 205.4 |
| Placebo | 140.0 |
Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician. (NCT00078897)
Timeframe: 3 to 5 years after baseline colonoscopy
| Intervention | Adenomas (Number) |
|---|---|
| Selenium | 302 |
| Placebo | 295 |
4 reviews available for celecoxib and Recrudescence
| Article | Year |
|---|---|
Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cycl | 2015 |
[Gastrointestinal bleeding].
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecox | 2015 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
14 trials available for celecoxib and Recrudescence
| Article | Year |
|---|---|
Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.
Topics: Cannabinoid Receptor Agonists; Cannabis; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Dronabinol | 2022 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular | 2017 |
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroscopy; Celecoxib; Cyclooxygenase | 2018 |
Celecoxib Versus Placebo in Tonsillectomy: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Celecoxib; Chronic Disease; Cycl | 2016 |
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cel | 2011 |
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; C-Reactive Protein; Cardiovascular | 2011 |
Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Body Mass Index; Celecoxib; Cohort Studies; Colorectal Neop | 2012 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; An | 2005 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Colitis, Ulc | 2006 |
Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Prog | 2006 |
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclophosphamide; Disease Progressi | 2006 |
16 other studies available for celecoxib and Recrudescence
| Article | Year |
|---|---|
Celecoxib as a Potential Treatment for Intractable Lymphatic Malformation.
Topics: Airway Obstruction; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Deglutition Disorders; Female; Hu | 2019 |
Recurrent endobronchial inflammatory myofibroblastic tumors: Novel treatment options.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Argon Plasma Coagulation; Bronchoscopy; Celecoxib; Child; F | 2020 |
Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Com | 2019 |
Immunomodulatory effect of Celecoxib on HMGB1/TLR4 pathway in a recurrent seizures model in immature rats.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Female; Hippocampus; HMGB1 Protein; Immunologic Factors; Kaini | 2018 |
The efficacy of celecoxib in preventing heterotopic ossification recurrence after open arthrolysis for post-traumatic elbow stiffness in adults.
Topics: Adolescent; Adult; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Elbow Injuries; Elbow Joi | 2015 |
Safe administration of celecoxib to a patient with repeated episodes of nephrotic syndrome induced by NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; | 2011 |
Hemicrania continua responds to cyclooxygenase-2 inhibitors.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Indomethacin; Lactones; Male; Migraine Disorde | 2002 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Celecoxib; Cohort Studies; Cyclooxyge | 2005 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; C | 2006 |
The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
Topics: Aged; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibito | 2007 |
Recurrent postoperative CRPS I in patients with abnormal preoperative sympathetic function.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerve Block; Carpal Tu | 2008 |
Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; C | 2008 |
Acute onset of auditory hallucinations after initiation of celecoxib therapy.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; | 2000 |
Responsiveness to celecoxib in chronic paroxysmal hemicrania.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Female; Humans; Migraine Disorders; Pyraz | 2000 |
Cyclooxygenase-2 inhibition and renal function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Burns, Chemical; Celecoxib; Cyclooxygenase 2; Diuresis; Fem | 2001 |